Biomarkers of Acute Renal Failure
Mayo Clinic Goals
August 2009
Currently, the Mayo Clinic Renal Function Laboratory is actively developing methodology for monitoring these and other urinary biomarkers of kidney injury. We have validated a rapid ELISA test for NGAL. Turnaround time for this is approximately 1 hour. As the literature evolves, we plan to develop additional biomarkers. A potential strategy might be to develop a multiplexed panel of acute kidney injury biomarkers that could be used to stage patients at risk. It’s also possible that many of these markers will have utility for following patients with chronic kidney disease in order to gauge the effectiveness of ongoing therapies to slow progression.
Mayo Clinic Goals |
Jump to section:
- Introduction
- Acute Kidney Injury
- Common Causes of Acute
- Progression From Pre-renal to Acute Tubular Necrosis
- Towards a Kidney Troponin
- Origin of Formed Elements in Urinalysis
- Urinanalysis: A Traditional Biomarker of AKI
- Hyaline Casts
- Renal Epithelial Cell Cast
- Leukocyte Cast
- RBC Cast
- Pigmented Cast
- Granular Cast
- Other Helpful Indices
- Potential Sources of Urinary Biomarkers
- NGAL as a Biomarker
- Studies Support NGAL as a Biomarker of AKI in the Following Situations
- Mayo Renal Laboratory Urinary NGAL Normals
- Normal Urinary NGAL Levels are Not Dependent on Age, but are Higher in Women than Men
- Ongoing Mayo Clinic Clinical Validation Study
- Ongoing Mayo Clinic Clinical Validation Study: Preliminary Results
- Study
- Other Potential Markers on the Horizon
- Mayo Clinic Goals
- Conclusions
- References
- Questions?
External
link
PDF
document
Excel
document
Word
document